New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 14, 2014
08:02 EDTCTRXCatamaran recent sell-off overdone, says Jefferies
Jefferies views the recent sell-off in shares of Catamaran as overdone. The firm attributes the move to concerns about the company's ability to meet Q1 consensus and win new contracts. Jefferies expects Catamaran shares to bounce back to the mid-$40s soon after the Q1 report and it keeps a Buy rating on the stock.
News For CTRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 18, 2015
10:47 EDTCTRXOptions with increasing implied volatility: KNDI CTRX
Subscribe for More Information
May 15, 2015
10:34 EDTCTRXOptions with increasing implied volatility
Subscribe for More Information
May 14, 2015
11:06 EDTCTRXOptions with increasing implied volatility
Subscribe for More Information
May 13, 2015
11:22 EDTCTRXOptions with increasing implied volatility
Subscribe for More Information
May 12, 2015
10:28 EDTCTRXOptions with increasing implied volatility: YELP HUM LULU CTRX
Subscribe for More Information
May 11, 2015
07:40 EDTCTRXFocus on Vertex will shift to pricing after Orkambi FDA meeting, WSJ says
An FDA advisory committee that meets Tuesday to decide whether to recommend approval of Vertexís Orkambi will be closely watched by health insurers and pharmacy-benefit managers concerned that the experimental cystic-fibrosis drug will be high-priced, said The Wall Street Journal. Vertex hasnít announced a price, but analyst at JPMorgan predict the drug will have a wholesale price of about $287,000 annually per patient. Publicly traded PBM owners include Catamaran (CTRX), which is being acquired by UnitedHealth (UNH), CVS Health (CVS) and Express Scripts (ESRX). Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use